Results 111 to 120 of about 11,784 (161)

Nanoparticulate Immunoactive Complex for Local Chemoimmunotherapy: From Murine Models to Pilot Canine Study. [PDF]

Cancer Res Commun
He Y, Zhao J, Kim JS, Broman MM, de Brot S, Meng F, Dhawan D, Utturkar SM, Shaevitz MH, Fourez LM, Knapp DW, Yeo Y.   +11 more
europepmc   +1 more source

Single-Cell Sequencing Reveals Novel Tumor Populations and Their Interplay with the Immune Microenvironment in a Pleomorphic Rhabdomyosarcoma. [PDF]

Int J Mol Sci
Kopantseva EE, Ikonnikov AV, Menyailo ME, Fetisov TI, Korobeynikova AA, Kirsanov KI, Tararykova AA, Bokhyan BY, Kozlov NA, Yakubovskaya MG, Denisov EV.   +10 more
europepmc   +1 more source

Targeting immune dysregulation in chronic spontaneous urticaria: beyond antihistamines. [PDF]

Korean J Intern Med
Ye YM.
europepmc   +1 more source

Cuproptosis-associated PDHA1 promotes sarcoma progression and immunotherapy responsiveness via the E2F1-PD-L1 axis: a multi-omics and clinical validation study. [PDF]

NPJ Precis Oncol
Qin H, Qi T, Yao N, Sheng W, Deng J, Qian J, Wang D, Zeng H, Weng J, Yang J, Yu F.   +10 more
europepmc   +1 more source

PIK3R1 as the Hidden Hand in Arrhythmogenic Right Ventricular Cardiomyopathy Inflammation: Weaving Transcriptomic Signatures with Structural Therapeutic Insights. [PDF]

Pharmaceuticals (Basel)
Azim N, Alsharidah AS, Alsharidah M, Khan N, Ahmad S.   +4 more
europepmc   +1 more source

From mechanism to management: CEREMAST perspectives on the intersection of HαT and clonal mast cell disorders. [PDF]

Front Allergy
Polivka L, Hermine O, Rossignol J.
europepmc   +1 more source

The FGFR1 N546K mutation confers resistance to pemigatinib in MLN-ZMYM2::FGFR1. [PDF]

Leukemia
Shoumariyeh K, Haug S, Schwaab J, Pfeil JK, Stappenbeck J, Schmitt-Graeff A, Naumann N, Waltemode G, Zeiser R, Miething C, Hofmann WK, Meggendorfer M, Diederichs S, Duyster J, Reiter A.   +14 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Successful treatment of mast cell sarcoma of the uterus with imatinib

International Journal of Hematology, 2011
Mast cell sarcoma is a rare disease characterized by localized, but destructive and rapid, growth of the tumor, high risk of distant metastasis, possibility of a leukemic phase, and poor prognosis. We report successful treatment of uterine mast cell sarcoma with imatinib in a 39-year-old woman who presented with abdominal distention and massive ascites.
Hong Bing, Ma, Xia, Xu, Wei Ping, Liu, Hong, Chang, Fan, Zeng, Yu Chun, Wang   +5 more
exaly   +3 more sources

Mast cell sarcoma of the scalp: The first sign of undisclosed systemic mastocytosis?

Pathology Research and Practice, 2012
Mastocytosis is a neoplastic disease of mast cells and their CD34+ precursors, including a heterogeneous group of disorders. It is characterized by abnormal growth and accumulation of mast cells in one or more organ systems. Mast cell sarcoma is an extremely rare and aggressive disease characterized by local proliferation of atypical mast cells ...
Jessica Falleti, Rossella De Cecio, Giulia Vita   +2 more
exaly   +3 more sources